RAVEL-TECHNOLOGIES
23.8.2022 19:28:16 CEST | Business Wire | Press release
Ravel Technologies S.A.S. (“Ravel'' or “Company”) proudly unveils several major patent-pending breakthroughs in Fully Homomorphic Encryption (FHE). Now 4 orders of magnitude faster than state-of-the-art, Ravel’s algorithmic discoveries are designed to make FHE finally scalable. The team is now building a sophisticated suite of fully encrypted technologies including the first fully encrypted SQL database equipped to query billions of encrypted data points, as well as advanced machine learning algorithms.
“Now that we have successfully overcome FHE’s biggest challenges, we will begin to put its uniquely powerful, protective capabilities to work,” explains Ravel CEO Mehdi Sabeg. “We have identified exciting opportunities in financial markets and privacy-preserving personalised advertising. We plan to address a full spectrum of vertically-diverse use cases, such as health data management, supply chain, financial services, and public services utilising our data sharing and analytics platform.”
Ravel includes a team of outstanding senior researchers in mathematics and is advised by Fields Medal Recipient Cedric Villani.
“Given the impressive, major algorithmic breakthroughs achieved by Ravel’s team, Ravel Fully Homomorphic Encryption (RHE) is orders of magnitude faster than state-of-the-art FHE schemes,” notes Villani. “With the continual increase of personal and industrial data being processed globally, privacy, and confidentiality protection are of paramount importance. Ravel’s breakthroughs bring an efficient and scalable answer to critical data privacy and security challenges.”
Ravel’s ability to process encrypted data with low latency and high throughput provides unparalleled de-identification capabilities that can also facilitate targeted advertisements with zero-knowledge of the consumer. Brands worldwide have long sought after exactly this solution, one that doesn’t infringe on the privacy of their users.
In the same fashion, Ravel can operate fully encrypted financial exchanges and remove certain market biases induced by plaintext data that can be exploited in the bidding process, for example. In this sector, confidentiality protection becomes increasingly important for large financial institutions starting to rely on transparent blockchain infrastructure.
“As we experienced during our Proof of Concept, Ravel has demonstrated that its technology can enable secure and efficient processing for high volumes of encrypted data,” BNP Paribas Group Chief Information Officer and Executive Committee Member Bernard Gavgani confirms. “They are well on their way to solving data sharing and analytics challenges in banking and finance for brands worldwide. We look forward to pursuing our collaboration.”
As Ravel strengthens its technological edge, the team is focused on scaling up its commercial growth, with a concentration on building out its presence across the US and European markets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005745/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corient Completes Acquisitions of Stonehage Fleming and Stanhope Capital Group; Global Assets Surpass US$500 Billion1.6.2026 08:15:00 CEST | Press release
Corient becomes the world’s largest non-bank wealth manager and multi-family office focused on serving ultra-high- and high-net-worth clients. Corient today announced the successful completion of its previously announced acquisitions of Stonehage Fleming and Stanhope Capital Group, marking a significant milestone in its continued global expansion. “This is an exciting moment for Corient and the clients we serve around the world,” said Kurt MacAlpine, Founding Partner and Chief Executive Officer of Corient. “We are thrilled to welcome our new Partners at Stonehage Fleming and Stanhope Capital Group to Corient as we continue building a truly global firm defined by partnership, collaboration and an unwavering commitment to client excellence.” With today’s announcement, Corient becomes the world’s largest non-bank wealth manager and multi-family office focused on ultra-high- and high-net-worth clients. The firm, established in 2020, operates under a client-first approach with complete fee
New Report From King: Mobile Games Sector Is Strategic Growth Driver for Europe, Contributing €6BN and Supporting 63,000+ Jobs1.6.2026 08:00:00 CEST | Press release
New report shows that more than 1,000 European mobile games studios contributed almost €6 billion to the European economy in 2025, supported more than 63,000 jobs1, and generated €7.53 billion in revenue from global audiences in 2025Mobile games are now the most popular way to play, accounting for 55% of global video games revenue, underlining their importance to Europe’s creative and digital economy King, the leading interactive entertainment company behind Candy Crush Saga, has today launched a first-of-its-kind report celebrating mobile games as a European success story,and spotlighting the sector’s contribution to jobs, growth, creativity and digital innovation across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260529376748/en/ The report,Mobile Matters: The Impact of Mobile Games for Europe, shows that in 2025 Europeanmobile games companies contributed an estimated €5.89 billion in economic value (GVA) to
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
